Minetta C. LiuMD
Minetta C. Liu, M.D., conducts patient-oriented research focused on two major areas: The development of clinically relevant molecular markers to allow for the most accurate prediction of treatment benefit and patient outcomes in solid tumor malignancies, and the development of novel therapeutics to improve survival in early-stage and metastatic breast cancer.
Dr. Liu leads a collaborative effort to optimize and validate platforms for isolating and analyzing circulating tumor cells (CTCs), cell-free DNA (cfDNA), and other blood components. Although her clinical expertise is in breast cancer, her "liquid biopsy" efforts are not restricted to any particular malignancy. Dr. Liu's current work includes the characterization of breast cancer stem cells in the peripheral circulation and the development of assays for the reliable detection of BRAF, EGFR, KRAS, and ESR1 mutations to assist in treatment selection and disease monitoring in melanoma, lung cancer, colorectal cancer, and breast cancer, respectively.